RubÃ©n FernÃ¡ndez-Santiago

List of Publications by Year
in descending order

62 papers	3,772 citations	186265 28 h-index	149698 56 g-index
63 all docs	63 docs citations	63 times ranked	5775 citing authors

#	Article	IF	Citations
1	Differential Phosphoâ€Signatures in Blood Cells Identify <scp>LRRK2 G2019S</scp> Carriers in Parkinson's Disease. Movement Disorders, 2022, 37, 1004-1015.	3.9	9
2	Altered expression of the immunoregulatory ligand-receptor pair CD200-CD200R1 in the brain of Parkinsonâ€™s disease patients. Npj Parkinson's Disease, 2022, 8, 27.	5.3	8
3	Smoking is associated with age at disease onset in Parkinson's disease. Parkinsonism and Related Disorders, 2022, 97, 79-83.	2.2	2
4	What have we learned from genome-wide association studies (GWAS) in Parkinson's disease?. Ageing Research Reviews, 2022, 79, 101648.	10.9	9
5	Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinsonâ€™s disease. Neurobiology of Aging, 2021, 97, 148.e17-148.e24.	3.1	16
6	Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets. JAMA Neurology, 2021, 78, 464.	9.0	95
7	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. Annals of Neurology, 2021, 90, 35-42.	5.3	29
8	Transcriptome analysis in LRRK2 and idiopathic Parkinsonâ€™s disease at different glucose levels. Npj Parkinson's Disease, 2021, 7, 109.	5.3	1
9	CCAAT/enhancer binding protein Î´ is a transcriptional repressor of Î±-synuclein. Cell Death and Differentiation, 2020, 27, 509-524.	11.2	14
10	<scp>MicroRNA</scp> Deregulation in Blood Serum Identifies Multiple System Atrophy Altered Pathways. Movement Disorders, 2020, 35, 1873-1879.	3.9	15
11	Nonsteroidal <scp>Antiâ€inflammatory</scp> Use and <scp>LRRK2</scp> Parkinson's Disease Penetrance. Movement Disorders, 2020, 35, 1755-1764.	3.9	57
12	Peripheral insulin and amylin levels in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 79, 91-96.	2.2	20
13	Disrupted Mitochondrial and Metabolic Plasticity Underlie Comorbidity between Age-Related and Degenerative Disorders as Parkinson Disease and Type 2 Diabetes Mellitus. Antioxidants, 2020, 9, 1063.	5.1	8
14	Transcriptomic differences in MSA clinical variants. Scientific Reports, 2020, 10, 10310.	3.3	7
15	Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score. Movement Disorders, 2020, 35, 774-780.	3.9	57
16	MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinsonâ€™s Disease Patients. Molecular Neurobiology, 2019, 56, 2092-2100.	4.0	17
17	Whole-genome DNA hyper-methylation in iPSC-derived dopaminergic neurons from Parkinsonâ€™s disease patients. Clinical Epigenetics, 2019, 11, 108.	4.1	16
18	Accumulation of mitochondrial 7S DNA in idiopathic and LRRK2 associated Parkinson's disease. EBioMedicine, 2019, 48, 554-567.	6.1	28

#	Article	IF	Citations
19	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	10.2	1,414
20	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Populationâ€Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. Movement Disorders, 2019, 34, 1851-1863.	3.9	47
21	SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease. Movement Disorders, 2019, 34, 1333-1344.	3.9	21
22	Cerebrospinal fluid cytokines in multiple system atrophy: A cross-sectional Catalan MSA registry study. Parkinsonism and Related Disorders, 2019, 65, 3-12.	2.2	26
23	HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	6.0	55
24	Parkinsonâ€™s disease as a systemic pathology. Aging, 2019, 11, 1081-1082.	3.1	3
25	Mitochondrial and autophagic alterations in skin fibroblasts from Parkinson disease patients with Parkin mutations. Aging, 2019, 11, 3750-3767.	3.1	25
26	Î±â€synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucineâ€rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain. Movement Disorders, 2018, 33, 637-641.	3.9	25
27	Transcriptional alterations in skin fibroblasts from Parkinson's disease patients with parkin mutations. Neurobiology of Aging, 2018, 65, 206-216.	3.1	13
28	The Small GTPase RAC1/CED-10 Is Essential in Maintaining Dopaminergic Neuron Function and Survival Against Î±-Synuclein-Induced Toxicity. Molecular Neurobiology, 2018, 55, 7533-7552.	4.0	40
29	Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy. Parkinsonism and Related Disorders, 2018, 46, 16-23.	2.2	32
30	Advances in Parkinsonâ€™s Disease: 200 Years Later. Frontiers in Neuroanatomy, 2018, 12, 113.	1.7	102
31	Exhaustion of mitochondrial and autophagic reserve may contribute to the development of LRRK2 G2019S -Parkinsonâ€™s disease. Journal of Translational Medicine, 2018, 16, 160.	4.4	22
32	MicroRNA alterations in iPSC-derived dopaminergic neurons from Parkinson disease patients. Neurobiology of Aging, 2018, 69, 283-291.	3.1	55
33	MAPT association with REM sleep behavior disorder. Neurology: Genetics, 2017, 3, e131.	1.9	10
34	A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimerâ€™s Disease Risk. Journal of Alzheimer's Disease, 2017, 56, 1065-1074.	2.6	5
35	The prodromal phase of leucineâ€rich repeat kinase 2â€“associated Parkinson disease: Clinical and imaging Studies. Movement Disorders, 2017, 32, 726-738.	3.9	48
36	Penetrance estimate of LRRK2 p.G2019S mutation in individuals of nonâ€Ashkenazi Jewish ancestry. Movement Disorders, 2017, 32, 1432-1438.	3.9	126

#	Article	IF	Citations
37	CSF microRNA Profiling in Alzheimerâ€™s Disease: a Screening and Validation Study. Molecular Neurobiology, 2017, 54, 6647-6654.	4.0	45
38	Discovering the 3â€² UTR-mediated regulation of alpha-synuclein. Nucleic Acids Research, 2017, 45, 12888-12903.	14.5	32
39	A Novel p.Glu298Lys Mutation in the ACMSD Gene in Sporadic Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2017, 7, 459-463.	2.8	15
40	Epigenetic Research of Neurodegenerative Disorders Using Patient iPSC-Based Models. Stem Cells International, 2016, 2016, 1-16.	2.5	13
41	Motor and nonmotor heterogeneity of LRRK2â€related and idiopathic Parkinson's disease. Movement Disorders, 2016, 31, 1192-1202.	3.9	102
42	Reply. Annals of Neurology, 2016, 79, 161-163.	5.3	3
43	Reply. Annals of Neurology, 2016, 79, 868-868.	5.3	0
44	Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers. Neurology, 2016, 86, 994-999.	1.1	114
45	Absence of LRRK2 mutations in a cohort of patients with idiopathic REM sleep behavior disorder. Neurology, 2016, 86, 1072-1073.	1.1	30
46	Aberrant epigenome in <scp>iPSC</scp> â€derived dopaminergic neurons from Parkinson's disease patients. EMBO Molecular Medicine, 2015, 7, 1529-1546.	6.9	117
47	Reply. Annals of Neurology, 2015, 78, 153-154.	5.3	1
48	Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers. PLoS ONE, 2015, 10, e0132368.	2.5	67
49	The <scp>MC1R</scp> melanoma risk variant p.<scp>R160W</scp> is associated with <scp>P</scp>arkinson disease. Annals of Neurology, 2015, 77, 889-894.	5.3	52
50	Micro<scp>RNA</scp> association with synucleinopathy conversion in rapid eye movement behavior disorder. Annals of Neurology, 2015, 77, 895-901.	5.3	50
51	Parkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinsonâ€™s disease. Cell Death and Disease, 2014, 5, e1364-e1364.	6.3	40
52	Identification of blood serum microâ€RNAs associated with idiopathic and LRRK2 Parkinson's disease. Journal of Neuroscience Research, 2014, 92, 1071-1077.	2.9	122
53	Fused in Sarcoma (FUS) gene mutations are not a frequent cause of essential tremor in Europeans. Neurobiology of Aging, 2013, 34, 2441.e9-2441.e11.	3.1	22
54	Mutant superoxide dismutase-1 indistinguishable from wild-type causes ALS. Human Molecular Genetics, 2012, 21, 3568-3574.	2.9	47

#	Article	IF	Citations
55	Age at Onset in LRRK2-Associated PD is Modified by SNCA Variants. Journal of Molecular Neuroscience, 2012, 48, 245-247.	2.3	34
56	No evidence of association of FLJ10986 and ITPR2 with ALS in a large German cohort. Neurobiology of Aging, 2011, 32, 551.e1-551.e4.	3.1	22
57	Lack of interaction of SNCA and MAPT genotypes in Parkinson's disease. European Journal of Neurology, 2011, 18, e32-e32.	3.3	12
58	Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Annals of Neurology, 2011, 70, 964-973.	5.3	168
59	The human G93A SOD1 phenotype closely resembles sporadic amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 764-767.	1.9	25
60	Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype. Journal of Medical Genetics, 2009, 46, 840-846.	3.2	70
61	Identification of novel Angiogenin (ANG) gene missense variants in German patients with amyotrophic lateral sclerosis. Journal of Neurology, 2009, 256, 1337-1342.	3.6	60
62	Possible gender-dependent association of vascular endothelial growth factor (VEGF) gene and ALS. Neurology, 2006, 66, 1929-1931.	1.1	29